These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 23219173)

  • 1. E2F1 apoptosis counterattacked: evil strikes back.
    Pützer BM; Engelmann D
    Trends Mol Med; 2013 Feb; 19(2):89-98. PubMed ID: 23219173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Translating DNA damage into cancer cell death-A roadmap for E2F1 apoptotic signalling and opportunities for new drug combinations to overcome chemoresistance.
    Engelmann D; Pützer BM
    Drug Resist Updat; 2010; 13(4-5):119-31. PubMed ID: 20675184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The E2F family and the role of E2F1 in apoptosis.
    Wu Z; Zheng S; Yu Q
    Int J Biochem Cell Biol; 2009 Dec; 41(12):2389-97. PubMed ID: 19539777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic factor EPC1 is a master regulator of DNA damage response by interacting with E2F1 to silence death and activate metastasis-related gene signatures.
    Wang Y; Alla V; Goody D; Gupta SK; Spitschak A; Wolkenhauer O; Pützer BM; Engelmann D
    Nucleic Acids Res; 2016 Jan; 44(1):117-33. PubMed ID: 26350215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. E2F1-dependent pathways are involved in amonafide analogue 7-d-induced DNA damage, G2/M arrest, and apoptosis in p53-deficient K562 cells.
    Li Y; Shao J; Shen K; Xu Y; Liu J; Qian X
    J Cell Biochem; 2012 Oct; 113(10):3165-77. PubMed ID: 22593008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The E2F1/Rb and p53/MDM2 pathways in DNA repair and apoptosis: understanding the crosstalk to develop novel strategies for prostate cancer radiotherapy.
    Udayakumar T; Shareef MM; Diaz DA; Ahmed MM; Pollack A
    Semin Radiat Oncol; 2010 Oct; 20(4):258-66. PubMed ID: 20832018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The tumor suppressor maspin mediates E2F1-induced sensitivity of cancer cells to chemotherapy.
    Ben Shachar B; Feldstein O; Hacohen D; Ginsberg D
    Mol Cancer Res; 2010 Mar; 8(3):363-72. PubMed ID: 20197383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcription factor NF-Y induces apoptosis in cells expressing wild-type p53 through E2F1 upregulation and p53 activation.
    Gurtner A; Fuschi P; Martelli F; Manni I; Artuso S; Simonte G; Ambrosino V; Antonini A; Folgiero V; Falcioni R; Sacchi A; Piaggio G
    Cancer Res; 2010 Dec; 70(23):9711-20. PubMed ID: 20952509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR signaling inhibits E2F1-induced apoptosis in vivo: implications for cancer therapy.
    Ginsberg D
    Sci STKE; 2007 Jan; 2007(371):pe4. PubMed ID: 17264315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. E2F1 uses the ATM signaling pathway to induce p53 and Chk2 phosphorylation and apoptosis.
    Powers JT; Hong S; Mayhew CN; Rogers PM; Knudsen ES; Johnson DG
    Mol Cancer Res; 2004 Apr; 2(4):203-14. PubMed ID: 15140942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. E2F1 suppresses skin carcinogenesis via the ARF-p53 pathway.
    Russell JL; Weaks RL; Berton TR; Johnson DG
    Oncogene; 2006 Feb; 25(6):867-76. PubMed ID: 16205640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The dark side of E2F1: in transit beyond apoptosis.
    Engelmann D; Pützer BM
    Cancer Res; 2012 Feb; 72(3):571-5. PubMed ID: 22298593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methylation-mediated regulation of E2F1 in DNA damage-induced cell death.
    Xie Q; Bai Y; Wu J; Sun Y; Wang Y; Zhang Y; Mei P; Yuan Z
    J Recept Signal Transduct Res; 2011 Apr; 31(2):139-46. PubMed ID: 21320024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular pathways: harnessing E2F1 regulation for prosenescence therapy in p53-defective cancer cells.
    Laine A; Westermarck J
    Clin Cancer Res; 2014 Jul; 20(14):3644-50. PubMed ID: 24788101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Jab1 is a specificity factor for E2F1-induced apoptosis.
    Hallstrom TC; Nevins JR
    Genes Dev; 2006 Mar; 20(5):613-23. PubMed ID: 16481464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. E2F1 death pathways as targets for cancer therapy.
    Pützer BM
    J Cell Mol Med; 2007; 11(2):239-51. PubMed ID: 17488475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inactivating E2f1 reverts apoptosis resistance and cancer sensitivity in Trp53-deficient mice.
    Wikonkal NM; Remenyik E; Knezevic D; Zhang W; Liu M; Zhao H; Berton TR; Johnson DG; Brash DE
    Nat Cell Biol; 2003 Jul; 5(7):655-60. PubMed ID: 12833065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteomic analysis of the E2F1 response in p53-negative cancer cells: new aspects in the regulation of cell survival and death.
    Li Z; Kreutzer M; Mikkat S; Mise N; Glocker MO; Pützer BM
    Proteomics; 2006 Nov; 6(21):5735-45. PubMed ID: 17001603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. E2F1 mediates ectopic proliferation and stage-specific p53-dependent apoptosis but not aberrant differentiation in the ocular lens of Rb deficient fetuses.
    Liu Y; Zacksenhaus E
    Oncogene; 2000 Dec; 19(52):6065-73. PubMed ID: 11146559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-15 and miR-16 are direct transcriptional targets of E2F1 that limit E2F-induced proliferation by targeting cyclin E.
    Ofir M; Hacohen D; Ginsberg D
    Mol Cancer Res; 2011 Apr; 9(4):440-7. PubMed ID: 21454377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.